Sanofi India Ltd

AI

Sanofi India Ltd

₹ 3,202 -0.91%
19 Nov - close price
About

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

Key Points

Parent Company:[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.

  • Market Cap ₹ 7,375 Cr.
  • Current Price ₹ 3,202
  • High / Low ₹ 4,638 / 2,758
  • Stock P/E 16.7
  • Book Value ₹ 374
  • Dividend Yield 2.34 %
  • ROCE 49.2 %
  • ROE 47.1 %
  • Face Value ₹ 10.0

Pros

  • Company is almost debt free.
  • Company's working capital requirements have reduced from 27.6 days to 20.4 days

Cons

  • Stock is trading at 8.56 times its book value
  • Debtor days have increased from 32.9 to 41.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
515 491 469 511 464 524 515
393 377 370 374 348 404 397
Operating Profit 122 114 100 137 116 120 118
OPM % 24% 23% 21% 27% 25% 23% 23%
57 82 77 41 21 2 14
Interest 1 0 0 0 0 0 0
Depreciation 9 9 9 9 9 9 10
Profit before tax 169 186 167 169 127 113 122
Tax % 27% 18% 18% 19% 19% 27% 25%
123 152 138 137 103 82 91
EPS in Rs 53.43 66.04 59.87 59.39 44.87 35.74 39.70
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2014 (S) Dec 2015 (S) Dec 2016 (S) Dec 2017 (S) Dec 2018 (S) Dec 2019 (S) Dec 2020 (S) Dec 2021 (S) Dec 2022 (S) Dec 2023 Dec 2024
1,977 2,193 2,367 2,460 2,771 3,071 2,902 2,957 2,770 1,996 2,013
1,639 1,817 1,832 1,921 2,146 2,403 2,186 2,194 2,066 1,508 1,522
Operating Profit 339 376 535 538 625 667 716 762 704 488 491
OPM % 17% 17% 23% 22% 23% 22% 25% 26% 25% 24% 24%
131 218 66 79 88 33 45 564 204 317 78
Interest 0 0 2 1 1 0 2 2 2 2 2
Depreciation 97 113 119 102 103 100 82 67 42 36 37
Profit before tax 373 481 480 515 610 600 677 1,258 864 767 531
Tax % 29% 33% 37% 37% 38% 31% 29% 25% 28% 21% 22%
264 322 304 326 381 414 478 944 621 603 413
EPS in Rs 114.61 139.78 132.26 141.74 165.48 180.09 207.65 410.61 269.83 262.13 179.70
Dividend Payout % 39% 46% 51% 50% 51% 194% 176% 119% 211% 64% 65%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 1%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -25%
Stock Price CAGR
10 Years: 2%
5 Years: -9%
3 Years: -12%
1 Year: -30%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 47%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2014 (S) Dec 2015 (S) Dec 2016 (S) Dec 2017 (S) Dec 2018 (S) Dec 2019 (S) Dec 2020 (S) Dec 2021 (S) Dec 2022 (S) Dec 2023 Dec 2024
Equity Capital 23 23 23 23 23 23 23 23 23 23 23
Reserves 1,463 1,604 1,860 2,003 2,196 2,419 2,096 2,203 1,253 992 838
0 0 0 0 0 0 23 25 24 19 19
742 778 658 751 765 802 777 811 772 681 732
Total Liabilities 2,228 2,405 2,541 2,778 2,984 3,244 2,918 3,061 2,072 1,715 1,612
648 877 817 769 733 499 464 334 306 315 312
CWIP 210 22 34 30 21 17 10 13 24 16 18
Investments 0 0 0 0 0 0 0 0 0 0 0
1,369 1,505 1,690 1,978 2,230 2,728 2,444 2,714 1,743 1,384 1,281
Total Assets 2,228 2,405 2,541 2,778 2,984 3,244 2,918 3,061 2,072 1,715 1,612

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2014 (S) Dec 2015 (S) Dec 2016 (S) Dec 2017 (S) Dec 2018 (S) Dec 2019 (S) Dec 2020 (S) Dec 2021 (S) Dec 2022 (S) Dec 2023 Dec 2024
265 213 322 435 374 412 611 559 399 230 462
61 36 -155 -79 -73 66 276 631 651 38 -180
-122 -147 -180 -188 -197 -183 -810 -849 -1,583 -878 -392
Net Cash Flow 205 102 -13 168 104 295 78 341 -533 -610 -111
Free Cash Flow 247 184 253 379 317 337 810 574 412 220 426
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 114% 93% 101% 118% 99% 96% 112% 111% 94% 97% 114%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Dec 2014 (S) Dec 2015 (S) Dec 2016 (S) Dec 2017 (S) Dec 2018 (S) Dec 2019 (S) Dec 2020 (S) Dec 2021 (S) Dec 2022 (S) Dec 2023 Dec 2024
Debtor Days 21 24 22 29 21 27 19 18 17 24 42
Inventory Days 179 173 169 151 154 127 107 110 125 254 186
Days Payable 122 81 79 119 110 100 93 105 109 112 151
Cash Conversion Cycle 78 115 112 61 65 54 33 22 33 167 77
Working Capital Days 26 9 79 17 18 35 -8 -20 -19 35 20
ROCE % 22% 26% 27% 26% 29% 28% 32% 35% 41% 49%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Total Employees
count

Log in to view insights

Please log in to see hidden values.

Login
Number of Countries Exported To
count
Production Volume at Manufacturing Sites (Total Galenic Units)
billion units
Number of Distributors
count
Lantus Market Share in Basal Insulin Segment
%
Manufacturing Cost per Unit at Goa Site
USD per unit

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

7 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40% 60.40%
6.31% 6.11% 5.81% 5.78% 5.64% 5.58% 5.61% 5.57% 5.55% 5.65% 5.69% 5.73%
22.51% 22.88% 22.60% 22.62% 22.94% 23.02% 23.06% 22.28% 21.30% 21.12% 19.87% 19.40%
10.78% 10.61% 11.21% 11.20% 11.04% 11.01% 10.94% 11.75% 12.75% 12.84% 14.05% 14.46%
No. of Shareholders 62,87061,84967,66266,21166,40168,19666,79071,39575,81375,75880,00580,089

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls